(VIANEWS) – The Market ended the session with NANOBIOTIX (NANO.PA) rising 16.72% to €5.06 on Tuesday, after five successive sessions in a row of losses. CAC 40 dropped 0.16% to €7,406.01, after three sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.
NANOBIOTIX’s last close was €4.34, 38.94% under its 52-week high of €7.10.
About NANOBIOTIX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.58.
Yearly Top and Bottom Value
NANOBIOTIX’s stock is valued at €5.06 at 22:34 EST, way below its 52-week high of €7.10 and way above its 52-week low of €1.61.
More news about NANOBIOTIX (NANO.PA).
